News 10|1|02

      home

      about us

      management

      board

      r & d

        pipeline

      EC Mechanism
      video
      news
      articles

      patents

      quarterly reports

      contact us

 
 


Click here for animation

 

  <  news & articles  >:

Cell>Point L.L.C. Preparing to Conduct Studies — 10|1|02

HOUSTON, Texas - October 2002 - Cell>Point L.L.C. is preparing to commence clinical biokinetic and biodistribution studies at The University of Texas M.D. Anderson Cancer Center on  99mTc-EC-Metronidazole,  99mTc-EC-Annexin V and  99mTc-EC-Cox-2. If results from the studies are as expected,Cell>Point will prepare and submit IND applications with the FDA for the three "kit" compounds.  99mTc-EC-Metronidazole will be studied as a tumor hypoxia marker,  99mTc-EC-Annexin V will be studied as a programmed cell death marker and  99m Tc-EC-Cox-2 will be studied as a tumor marker.

Cell>Point is also preparing to commence clinical biokinetic and biodistribution studies on  99mTc-EC-Deoxyglucose for lymphoma. If results from the study are as expected,Cell>Point will prepare and submit an amendment to its  99m Tc-EC-Deoxyglucose IND (63,698) to include lymphoma as an additional indication.

 

© copyright 2001-2007|Cell>Point L.L.C | all rights reserved | maintained by Link2City.com  

Terry Colip 

Home | About Us | Management Team | Scientific Advisory Board | Corporate fact Sheet
EC Mechanism of Action | Video |  R & D | Agents Pipeline | News | Articles | Patents | Corp Financials | Contact Us